These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28365026)

  • 1. Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice.
    Johnson PK; Mendelson MM; Baker A; Ryan HH; Warren S; Graham D; Griggs SS; Desai NK; Yellen E; Buckley L; Zachariah JP; de Ferranti SD
    J Pediatr; 2017 Jun; 185():94-98.e1. PubMed ID: 28365026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins.
    Kurnik D; Hochman I; Vesterman-Landes J; Kenig T; Katzir I; Lomnicky Y; Halkin H; Loebstein R
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):36-41. PubMed ID: 22211469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D.
    Riphagen IJ; van der Veer E; Muskiet FA; DeJongste MJ
    Curr Med Res Opin; 2012 Jul; 28(7):1247-52. PubMed ID: 22686958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy.
    Nogueira AA; Strunz CM; Takada JY; Mansur AP
    Biomark Med; 2019 Jun; 13(8):619-626. PubMed ID: 31157560
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-induced myopathies.
    Tomaszewski M; Stępień KM; Tomaszewska J; Czuczwar SJ
    Pharmacol Rep; 2011; 63(4):859-66. PubMed ID: 22001973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.
    Smith CC; Bernstein LI; Davis RB; Rind DM; Shmerling RH
    Arch Intern Med; 2003 Mar; 163(6):688-92. PubMed ID: 12639201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin-associated myopathy.
    Thompson PD; Clarkson P; Karas RH
    JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of statins on creatine kinase levels before and after a marathon run.
    Parker BA; Augeri AL; Capizzi JA; Ballard KD; Troyanos C; Baggish AL; D'Hemecourt PA; Thompson PD
    Am J Cardiol; 2012 Jan; 109(2):282-7. PubMed ID: 22036108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing statin myopathy.
    Venero CV; Thompson PD
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):121-36. PubMed ID: 19217515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Creatine kinase increase under simvastatin--therapeutic consequences?].
    Rasche-Schürmann CC; Picksak G; Stichtenoth DO
    Med Monatsschr Pharm; 2008 Jan; 31(1):25-7. PubMed ID: 18522017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical and muscular pathological features of statin-induced myopathy].
    Meng L; Lu Y; Zhang W; Wang Z; Lyu H; Yuan Y
    Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):716-20. PubMed ID: 26674629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.
    Floyd JS; Brody JA; Tiniakou E; Psaty BM; Mammen A
    Muscle Nerve; 2016 Jun; 54(1):142-4. PubMed ID: 27038110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk for significant creatine kinase elevation with statins.
    Stolcpart RS; Olson KL; Delate T; Rasmussen J; Rehring TF; Merenich JA
    Am J Cardiovasc Drugs; 2010; 10(3):187-92. PubMed ID: 20524720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
    Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
    Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
    Fung EC; Crook MA
    Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin intolerance.
    Ahmad Z
    Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle toxicity with statins.
    Hedenmalm K; Alvan G; Ohagen P; Dahl ML
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):223-31. PubMed ID: 20014178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low plasma vitamin D levels and muscle-related adverse effects in statin users.
    Eisen A; Lev E; Iakobishvilli Z; Porter A; Brosh D; Hasdai D; Mager A
    Isr Med Assoc J; 2014 Jan; 16(1):42-5. PubMed ID: 24575504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.